Search companies

Live

CERETAS LIMITED (ASX: CTS)

Health care · News and insights

Price unavailable

Latest CTS announcements

Ceretas Completes Ultrasound Device Prototypes, Triggering Final Grant Payment

2026-10-30 · Health care

CTS: $0.920 +2.22% · MC: $67M

Ceretas completed functional prototypes of navigation software and a lift-assist device intended to enable single-operator ultrasound treatment and reduce device costs. The milestone triggered the final payment under its government-backed grant. The company also secured full ownership of its core intellectual property during the quarter and said its IPO fully funded its Phase 2 Alzheimer’s trial. Ceretas reported yesterday that the trial’s first patient had enrolled ahead of its year-end target.

Updated 2026-10-30 10:39
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments

Ceretas Enrols First Patient In Phase 2 Alzheimer’s Trial

2026-10-29 · Health care

CTS: $0.900 +4.65% · MC: $67M

Ceretas has enrolled the first patient in its Phase 2 CERE-CALM trial, testing focused ultrasound as a treatment for behavioural symptoms in people with Alzheimer’s disease. The fully funded study is targeting at least 60 participants, with recruitment underway in Sydney and completion anticipated in the first half of 2028. It follows a 12-patient Phase 1 study that reported favourable safety and tolerability, alongside preliminary signs of symptom improvement.

Updated 2026-10-29 10:07
Share
SourcesFirst Patient Enrolled in Phase 2 CERE-CALM Clinical Trial
Comments